Anna Ferrari

Biosketch / Results /

Anna Ferrari, M.D.

Professor;
Departments of Medicine (Perlmutter Cancer Center) and Medicine (Residency Program)
NYU Medical Oncology Associates

Clinical Addresses

160 E. 34TH STREET, 8TH FLOOR
NEW YORK, NY 10016
Hours: Wed. 8 - 5; Thu. 8 - 5
Handicap Access: yes
Phone: 212-731-5389
Fax: 212-731-5545

« Back to Results

Medical Specialties

Cancer, Medical Oncology

Medical Expertise

Genitourinary Cancer, Bladder Cancer, Metastatic Prostate Cancer, Kidney Cancer, Prostate Cancer, Testicular Cancer, Recurrent Prostate Cancer

Clinical Responsibilities

I am a clinician?scientist with an established translational research record in prostate cancer (PC). My experience includes clinical trial development based on preclinical testing of novel agents and molecular correlates of progression. Examples of my basic-therapeutic, goal-oriented experience are: (1)preclinical and clinical testing of novel drug combinations to simultaneously block either AR ligand activation and histone deacetylases (LBH589/Panobinostat) in order to reverse resistance to hormone therapy (ph I/II NYU-08479 /DOD Consortium/ Novartis) or cross-talk of the AR with PI3/Akt/mTor signaling in order to avoid castration in recurrent PC (ECOG 2809/CTEP). (2)the identification of a repressor of the androgen receptor (AR) linked to overexpression of AR in an androgen-independent LNCaP derivative and castration-resistant PC (CRPC) specimens; and (3) experience in conducting tissue correlative studies interacting with multiple basic and clinical investigators include: (a) R21CA79918-01, a 400-patient international trial of molecular staging of occult micrometastases in pathologically normal lymph nodes as a prognostic indicator of biochemical recurrence; and (b) RO1CA098135-01, a study of the role of KLF6 gene alterations in PC progression. In this study we first observed that KLF6 splicing became diverse and magnified in neo-androgen deprived PC tissues (neoADT) and conferred AI PC growth in vitro. Currently, I am the translational science chair for the ECOG GU Committee, and, in this capacity, I recently designed and recruited expert investigators in next-generation transcriptome and immunohistochemistry analysis for correlative studies for a major Phase III adjuvant hormone therapy trial.

Languages

French, Spanish

Insurance

AETNA HMO, AETNA INDEMNITY, AETNA MEDICARE, AETNA POS, AETNA PPO/EPO, AFFINITY, CIGNA EPO/POS, Cigna PPO, EBCBS EPO, EBCBS HLTHY NY, EBCBS HMO, EBCBS INDEMNITY, EBCBS MEDIBLUE, EBCBS POS, EBCBS PPO, ELDERPLAN, GHI CBP, HEALTHREPUBLIC, HIP ACCESS I, HIP ACCESS II, HIP CHLD HLTH, HIP EPO/PPO, HIP HMO, HIP MEDICARE, HIP POS, LOCAL 1199 PPO, MAGNACARE PPO, METROPLUS CHLD HLTH, METROPLUS EXCHANGE PLANS, METROPLUS FAM HLTH, MULTIPLAN/PHCS PPO, Medicare, MetroPlus Medicaid, NY MEDICAID, NYS EMPIRE PLAN, OSCAR, OXFORD EXCHANGE, OXFORD FREEDOM, Oxford Liberty, Oxford Medicare, Railroad Medicare, Tricare, UHC COMMUNITY & STATE PLAN, UHC EPO, UHC HMO, UHC MEDICARE, UHC POS, UHC PPO, UHC TOP TIER, UNITED EXCHANGE- COMPASS UPN Elite, WELLCARE CHLD HLTH, WELLCARE FAM HLTH, WELLCARE MEDICAID, WELLCARE MEDICARE

Insurance Disclaimer: Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have changed.

« Back to Results

Board Certification

1986 — Ab Internal Medicine - Internal Medicine
1987 — Ab Internal Medicine (Medical Oncology)

Education

1974 — University of Uruguay, Medical Education
1975-1978 — Universidad de la Republica del (Medicine), Residency Training
1980-1982 — National Cancer Institute (Cancer Research), Clinical Fellowships
1982-1985 — Union Memorial Hospital (Medicine), Residency Training
1982-1986 — Bronx Municipal Hospital Center (Hematology), Clinical Fellowships
1986-1988 — New York University Medical Center (Oncology), Clinical Fellowships

« Back to Results

All data from NYU Health Sciences Library Faculty Bibliography — -

Contact:
http://hsl.med.nyu.edu/faculty-bibliography-search

Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial
Harrop, Richard; Chu, Franklin; Gabrail, Nashat; Srinivas, Sandy; Blount, Daniel; Ferrari, Anna
2013 Sep;62(9):1511-1520, Cancer immunology immunotherapy
— id: 684652, year: 2013, vol: 62, page: 1511, stat: Journal Article,

Effect of inhibition of the PI3K/Akt/mTOR pathway on AR splicing and downstream targets
Liu, X M; Gomez-Pinillos, A; Shah, P; Lavilla, C; Ferrari, A C
2013 20 Feb 2013;31(6):-, Journal of clinical oncology
— id: 395102, year: 2013, vol: 31, page: , stat: Journal Article,

mTOR Signaling Pathway and mTOR Inhibitors in Cancer Therapy
Gomez-Pinillos, Alejandro; Ferrari, Anna C
2012 Jun;26(3):553-555, Hematology-oncology clinics of North America
— id: 165620, year: 2012, vol: 26, page: 553, stat: Journal Article,

Alternative splicing of Kruppel-like factor 6 (KLF6) enriched in human androgen-deprived prostate cancer (PC)
Liu, X; Alejandro, G -P; Loder, C; Santa, Pau E C -D; Quiao, R F; Unger, P D; Kurek, R; Oddoux, C; Melamed, J; Gallagher, R E; Mandeli, J P; Ferrari, A C
2012 20 May 2012;30(15):-, Journal of clinical oncology
— id: 249912, year: 2012, vol: 30, page: , stat: Journal Article,

KLF6 Loss of Function in Human Prostate Cancer Progression Is Implicated in Resistance to Androgen Deprivation
Liu, Xiaomei; Gomez-Pinillos, Alejandro; Loder, Charisse; Carrillo-de Santa Pau, Enrique; Qiao, Ruifang; Unger, Pamela D; Kurek, Ralf; Oddoux, Carole; Melamed, Jonathan; Gallagher, Robert E; Mandeli, John; Ferrari, Anna C
2012 Sep;181(3):1007-1016, American journal of pathology
— id: 177238, year: 2012, vol: 181, page: 1007, stat: Journal Article,

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer
Tolcher, A W; Quinn, D I; Ferrari, A; Ahmann, F; Giaccone, G; Drake, T; Keating, A; de Bono, J S
2012 Apr;23(4):968-973, Annals of oncology
— id: 165678, year: 2012, vol: 23, page: 968, stat: Journal Article,

Immunotherapy in the treatment of advanced prostate cancer
Djavan, Bob; Nelson, Kathleen; Kazzazi, Amir; Bruhn, Aron; Sadri, Helen; Gomez-Pinillos, Alejandro; Ferrari, Anna C
2011 Oct;18(5):5865-5874, Canadian journal of urology
— id: 139745, year: 2011, vol: 18, page: 5865, stat: Journal Article,

Natura-alpha targets forkhead box m1 and inhibits androgen-dependent and -independent prostate cancer growth and invasion
Li, Yirong; Ligr, Martin; McCarron, James P; Daniels, Garrett; Zhang, David; Zhao, Xin; Ye, Fei; Wang, Jinhua; Liu, Xiaomei; Osman, Iman; Mencher, Simon K; Lepor, Hebert; Wang, Long G; Ferrari, Anna; Lee, Peng
2011 Jul;17(13):4414-4424, Clinical cancer research
— id: 174599, year: 2011, vol: 17, page: 4414, stat: Journal Article,

Sipuleucel-T immunotherapy for castration-resistant prostate cancer
Kantoff, Philip W; Higano, Celestia S; Shore, Neal D; Berger, E Roy; Small, Eric J; Penson, David F; Redfern, Charles H; Ferrari, Anna C; Dreicer, Robert; Sims, Robert B; Xu, Yi; Frohlich, Mark W; Schellhammer, Paul F
2010 Jul;363(5):411-422, New England journal of medicine
— id: 684662, year: 2010, vol: 363, page: 411, stat: Journal Article,

Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels
Liu, Xiaomei; Gomez-Pinillos, Alejandro; Liu, Xiaojun; Johnson, Edward M; Ferrari, Anna C
2010 Feb 1;70(2):179-189, Prostate
— id: 105961, year: 2010, vol: 70, page: 179, stat: Journal Article,

The link between pain patient and analgesic medication is greater in migraine than in rheumatic disease patients
Ferrari, A; Leone, S; Tacchi, R; Ferri, C; Gallesi, D; Giuggioli, D; Bertolini, A
2009 Jan;29(1):31-37, Cephalalgia
— id: 800482, year: 2009, vol: 29, page: 31, stat: Journal Article,

Sequential and intermittent docetaxel (D) and imatinib (Im) in hormone-refractory prostate cancer patients (NYU 04-47)
Gmez-Pinillos A.; Ballard H.; Shelton G.; Reilly M.M.; Chachoua A.; Taneja S.; Ferrari A.C.
2009 ;27(15 Suppl 1):?-? #e16108, Journal of clinical oncology
— id: 111804, year: 2009, vol: 27, page: ?, stat: Journal Article,

LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion
Li, Yirong; Wang, Longgui; Zhang, Miao; Melamed, Jonathan; Liu, Xiaomei; Reiter, Robert; Wei, Jianjun; Peng, Yi; Zou, Xuanyi; Pellicer, Angel; Garabedian, Michael J; Ferrari, Anna; Lee, Peng
2009 Apr 15;69(8):3332-3338, Cancer research
— id: 99128, year: 2009, vol: 69, page: 3332, stat: Journal Article,

Lef1 Expression in Androgen-Independent Prostate Cancer
Zhang, M; Li, YR; Wang, LG; Melamed, J; Liu, XM; Wei, JJ; Peng, Y; Pellicer, A; Garabedian, MJ; Ferrari, A; Lee, P
2009 ;89:921-921, Laboratory investigation
— id: 104576, year: 2009, vol: 89, page: 921, stat: Journal Article,

Lef1 Expression in Androgen-Independent Prostate Cancer
Zhang, M; Li, YR; Wang, LG; Melamed, J; Liu, XM; Wei, JJ; Peng, Y; Pellicer, A; Garabedian, MJ; Ferrari, A; Lee, P
2009 ;22(Suppl 1):203A-203A 921, Modern pathology
— id: 104577, year: 2009, vol: 22, page: 203A, stat: Journal Article,

Androgen receptor overexpression in prostate cancer linked to Pur alpha loss from a novel repressor complex
Wang, Longgui G; Johnson, Edward M; Kinoshita, Yayoi; Babb, James S; Buckley, Michael T; Liebes, Leonard F; Melamed, Jonathan; Liu, Xiao-Mei; Kurek, Ralf; Ossowski, Liliana; Ferrari, Anna C
2008 Apr 15;68(8):2678-2688, Cancer research
— id: 95063, year: 2008, vol: 68, page: 2678, stat: Journal Article,

Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer
Wang, L G; Beklemisheva, A; Liu, X M; Ferrari, A C; Feng, J; Chiao, J W
2007 Jan;46(1):24-31, Molecular carcinogenesis
— id: 70302, year: 2007, vol: 46, page: 24, stat: Journal Article,

Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment
Ferrari, Anna C; Stone, Nelson N; Kurek, Ralf; Mulligan, Elizabeth; McGregor, Roy; Stock, Richard; Unger, Pamela; Tunn, Ulf; Kaisary, Amir; Droller, Michael; Hall, Simon; Renneberg, Heiner; Livak, Kenneth J; Gallagher, Robert E; Mandeli, John
2006 Jul 1;24(19):3081-3088, Journal of clinical oncology
— id: 65800, year: 2006, vol: 24, page: 3081, stat: Journal Article,

Mithramycin targets sp1 and the androgen receptor transcription level-potential therapeutic role in advanced prostate cancer
Wang, Long G; Ferrari, Anna C
2006 ;1:19-31, Translational oncogenomics
— id: 346542, year: 2006, vol: 1, page: 19, stat: Journal Article,

Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells
Liu, X M; Jiang, J D; Ferrari, A C; Budman, D R; Wang, L G
2003 Oct;89(8):1566-1573, British journal of cancer
— id: 442312, year: 2003, vol: 89, page: 1566, stat: Journal Article,

A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma
Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
2001 Jun 1;91(11):2039-2045, Cancer
— id: 34610, year: 2001, vol: 91, page: 2039, stat: Journal Article,

The FGF-related oncogene, K-FGF, maps to human chromosome region 11q13, possibly near int-2
Huebner K; Ferrari AC; Delli Bovi P; Croce CM; Basilico C
1988 ;3(3):263-270, Oncogene research
— id: 14424, year: 1988, vol: 3, page: 263, stat: Journal Article,

A phase I trial of aziridinylbenzoquinone (NSC 192986) in patients with previously treated acute leukemia
Van Echo, D A; Schulman, P; Budman, D R; Ferrari, A; Wiernik, P H
1982 Aug;5(4):405-410, American journal of clinical oncology
— id: 442792, year: 1982, vol: 5, page: 405, stat: Journal Article,